Filippo Russo

653 total citations
32 papers, 432 citations indexed

About

Filippo Russo is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Filippo Russo has authored 32 papers receiving a total of 432 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pathology and Forensic Medicine, 11 papers in Genetics and 11 papers in Oncology. Recurrent topics in Filippo Russo's work include Lymphoma Diagnosis and Treatment (20 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Gut microbiota and health (3 papers). Filippo Russo is often cited by papers focused on Lymphoma Diagnosis and Treatment (20 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Gut microbiota and health (3 papers). Filippo Russo collaborates with scholars based in Italy, Greece and United Kingdom. Filippo Russo's co-authors include Antonio Pinto, Gaetano Corazzelli, Gaetana Capobianco, Ferdinando Frigeri, Gianpaolo Marcacci, Manuela Arcamone, Cristina Becchimanzi, Antonello Paduano, Nicola Caporaso and Raffaele Sacchi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal Of Pathology.

In The Last Decade

Filippo Russo

31 papers receiving 418 citations

Peers

Countries citing papers authored by Filippo Russo

Since Specialization

Citations

This map shows the geographic impact of Filippo Russo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Filippo Russo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Filippo Russo more than expected).

Fields of papers citing papers by Filippo Russo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Filippo Russo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Filippo Russo. The network helps show where Filippo Russo may publish in the future.

Co-authorship network of co-authors of Filippo Russo

This figure shows the co-authorship network connecting the top 25 collaborators of Filippo Russo. A scholar is included among the top collaborators of Filippo Russo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Filippo Russo. Filippo Russo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genes of the “regulation of lymphocyte activation” pathway may influence immune cells infiltration in growth hormone secreting pituitary tumors 2025 ·Pituitary ·Sabrina Chiloiro, (unknown), Giovanni Luca Scaglione, Filippo Russo, Carmela Nardelli, Antonella Giampietro, Pier Paolo Mattogno, Liverana Lauretti, Guido Rindi, Laura De Marinis, (unknown), Antonio Bianchi, Francesco Doglietto, (unknown), Alfredo Pontecorvi	0
2	Insights into Porphyromonas somerae in Bladder Cancer Patients: Urinary Detection by ddPCR 2024 ·Microorganisms ·Filippo Russo, Speranza Esposito, (unknown), Savio Domenico Pandolfo, Achille Aveta, Felice Amato, Carmela Nardelli, Ciro Imbimbo, Lucio Pastore, Giuseppe Castaldo	8
3	Microbiome Profiling in Bladder Cancer Patients Using the First-morning Urine Sample 2023 ·European Urology Open Science ·Carmela Nardelli, Achille Aveta, Savio Domenico Pandolfo, (unknown), Filippo Russo, Ciro Imbimbo, Giuseppe Castaldo, Lucio Pastore	34
4	Identification and Functional Analysis of Known and New Mutations in the Transcription Factor KLF1 Linked with β-Thalassemia-like Phenotypes 2023 ·Biology ·(unknown), (unknown), (unknown), Elena Cesaro, Filippo Russo, Paola Izzo, Alexandros Makis, Michela Grosso	5
5	Nasal Microbiome in COVID-19: A Potential Role of Corynebacterium in Anosmia 2022 ·Current Microbiology ·Carmela Nardelli, Giovanni Luca Scaglione, D. Testa, (unknown), Filippo Russo, Carmela Di Domenico, (unknown), Massimo Zollo, F Corrado, Paola Salvatore, Biagio Pinchera, Ivan Gentile, (unknown)	5
6	Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice 2021 ·Journal of Personalized Medicine ·Sabrina Chiloiro, Filippo Russo, Tommaso Tartaglione, (unknown)	9
7	Characterisation of volatile compounds in Cilento (Italy) figs (Ficus caricaL.) cv. Dottato as affected by the drying process 2017 ·International Journal of Food Properties ·Filippo Russo, Nicola Caporaso, Antonello Paduano, Raffaele Sacchi	12
8	Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas 2011 ·European Journal Of Haematology ·Gaetano Corazzelli, Ferdinando Frigeri, Manuela Arcamone, Luigi Aloj, Gaetana Capobianco, Cristina Becchimanzi, Emanuela Morelli, Francesco Volzone, Gianpaolo Marcacci, Filippo Russo, Rosaria De Filippi, Secondo Lastoria, Antonio Pinto	1
9	RD‐CODOX‐M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B‐cell lymphoma 2011 ·British Journal of Haematology ·Gaetano Corazzelli, Ferdinando Frigeri, Filippo Russo, Chiara Frairia, Manuela Arcamone, Gennaro Esposito, Annarosaria De Chiara, Emanuela Morelli, Gaetana Capobianco, Cristina Becchimanzi, Francesco Volzone, (unknown), G. Marcacci, Rosaria De Filippi, Umberto Vitolo, Antonio Pinto	57
10	Biweekly rituximab, cyclophosphamide, vincristine, non‐pegylated liposome‐encapsulated doxorubicin and prednisone (R‐COMP‐14) in elderly patients with poor‐risk diffuse large B‐cell lymphoma and moderate to high ‘life threat’ impact cardiopathy 2011 ·British Journal of Haematology ·Gaetano Corazzelli, Ferdinando Frigeri, Manuela Arcamone, (unknown), (unknown), Emanuela Morelli, Alfonso Amore, Gaetana Capobianco, (unknown), Cristina Becchimanzi, Francesco Volzone, Gianpaolo Marcacci, Filippo Russo, Rosaria De Filippi, Lucia Mastrullo, Antonio Pinto	41
11	Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial. 2010 ·Blood ·Gaetano Corazzelli, Ferdinando Frigeri, Gianpaolo Marcacci, Cristina Becchimanzi, Gaetana Capobianco, Manuela Arcamone, Emanuela Morelli, Francesco Volzone, Filippo Russo, Antonio Pinto	11
12	Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma 2009 ·Cancer Chemotherapy and Pharmacology ·Gaetano Corazzelli, Gaetana Capobianco, Manuela Arcamone, Pier Ferruccio Ballerini, Emilio Iannitto, Filippo Russo, Ferdinando Frigeri, Cristina Becchimanzi, Gianpaolo Marcacci, Annarosaria De Chiara, Antonio Pinto	58
13	Expression of the Brain Transcription Factor OTX1 Occurs in a Subset of Normal Germinal-Center B Cells and in Aggressive Non-Hodgkin Lymphoma 2009 ·American Journal Of Pathology ·Daniela Omodei, Dario Acampora, Filippo Russo, Rosaria De Filippi, Valeria Severino, Raffaele Di Francia, Ferdinando Frigeri, Pietro Mancuso, A. Chiara, Antonio Pinto, Stefano Casola, Antonio Simeone	22
14	Thoracic stop-flow perfusion for refractory lymphoma: a phase I-II evaluation trial. 2009 ·PubMed ·(unknown), Stefano Guadagni, Filippo Russo, Giancarlo Palumbo, Giammaria Fiorentini, Andrea Mambrini, Maurizio Cantore, (unknown), Antonio Pinto, Gianfranco Amicucci	1
15	Abnormalities in Serum Free-Immunoglobulin Light Chains Show a High and Differential Frequency among WHO Subtypes of B-Cell Non-Hodgkin’s Lymphoma (NHL) and May Turn of Value for Therapeutic Monitoring: A Study of 354 Newly Diagnosed Patients 2008 ·Blood ·Antonio Pinto, Rosaria De Filippi, (unknown), Raffaele Di Francia, (unknown), Ferdinando Frigeri, Filippo Russo, (unknown), (unknown)	1
16	Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study 2006 ·Annals of Oncology ·Gaetano Corazzelli, Filippo Russo, Giampiero Capobianco, Gianpaolo Marcacci, (unknown), Antonio Pinto	33
17	Tandem high‐dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: A monocenter prospective study 2006 ·American Journal of Hematology ·Luca Castagna, Massimo Magagnoli, Monica Balzarotti, Barbara Sarina, Licia Siracusano, Andrea Nozza, Elisabetta Todisco, Stéfania Bramanti, Rita Mazza, Filippo Russo, Inna Timofeeva, Armando Santoro	22
18	Pentostatin (2'-deoxycoformycin) for the treatment of hepatosplenic gammadelta T-cell lymphomas. 2005 ·PubMed ·Gaetano Corazzelli, Gaetana Capobianco, Filippo Russo, Ferdinando Frigeri, Donatella Aldinucci, Antonio Pinto	19
19	Gemcitabine, Ifosfamide, Oxaliplatin and Rituximab (R-GIFOX), a New Effective Cytoreductive/Mobilizing Salvage Regimen for Relapsed and Refractory Aggressive Non-Hodgkin’s Lymphoma: Results of a Pilot Study. 2005 ·Blood ·Gaetano Corazzelli, Filippo Russo, Gaetana Capobianco, Gianpaolo Marcacci, (unknown), Antonio Pinto	3
20	Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma 2002 ·The American Journal of Surgery ·Stefano Guadagni, Filippo Russo, Carlo Riccardo Rossi, Pierluigi Pilati, Diego Miotto, Giammaria Fiorentini, Marcello Deraco, Mario Santinami, Giancarlo Palumbo, Marco Valenti, Gianfranco Amicucci	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact